Chong P H, Seeger J D
Department of Pharmacy-Clinical Services, Cook County Hospital, University of Illinois at Chicago College of Pharmacy, 60612-9985, USA.
Pharmacotherapy. 1997 Nov-Dec;17(6):1157-77.
Atorvastatin calcium is an HMG-coenzyme A (CoA) reductase inhibitor that was approved by the Food and Drug Administration on December 17, 1996. Like other such agents, it inhibits the action of HMG-CoA reductase and thereby decreases endogenous cholesterol synthesis, leading to a decrease in circulating low-density lipoprotein cholesterol. In addition to its effect on lipoprotein profile, atorvastatin reduces triglycerides to a greater extent than other HMG-CoA reductase inhibitors. These actions occur in a dose-dependent fashion. The adverse effect profile is similar to that of other agents in this class. Indications for atorvastatin include primary hypercholesterolemia as well as other lipid disorders.
阿托伐他汀钙是一种HMG辅酶A（CoA）还原酶抑制剂，于1996年12月17日获得美国食品药品监督管理局批准。与其他此类药物一样，它抑制HMG-CoA还原酶的作用，从而减少内源性胆固醇合成，导致循环中的低密度脂蛋白胆固醇降低。除了对脂蛋白谱的影响外，阿托伐他汀比其他HMG-CoA还原酶抑制剂更能降低甘油三酯。这些作用呈剂量依赖性。不良反应谱与该类中的其他药物相似。阿托伐他汀的适应症包括原发性高胆固醇血症以及其他脂质紊乱。
